Trial Profile
Phase II, Double-blind, Placebo-controlled, Crossover Study Evaluating a 5HT3 Antagonist Plus Dexamethasone With or Without Fosaprepitant in Patients With Advanced NSCLC Receiving Carboplatin Based Chemotherapy
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Fosaprepitant (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 08 Apr 2015 New trial record